PHILADELPHIA, Nov. 6, 2017 /CNW/ -- Hemispherx Biopharma, Inc. (NYSE American: HEB), based in Philadelphia, focused on pharmaceuticals, today announced that the November 2 presentation from Chief Executive Officer, Thomas K. Equels, M.S. J.D., is now available for on-demand viewing at VirtualInvestorConferences.com.
Hemispherx Biopharma, Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.
The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.
The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Hemispherx Biopharma, Inc.
For further information: Hemispherx Biopharma, Inc., Investor Relations Phone Number: 800-778-4042, Email: [email protected]; VirtualInvestorConferences.com, John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, 350 Hudson Street | 3rd Floor | New York, NY 10014, Phone 201 360 6767 | Mobile 212 729 8350, [email protected]